MONTE ROSA THERAPEUTICS INC (GLUE) Stock Price, Forecast & Analysis
NASDAQ:GLUE • US61225M1027
GLUE Key Statistics, Chart & Performance
The current stock price of GLUE is 18.28 USD. In the past month the price decreased by -25.2%. In the past year, price increased by 193.89%.
GLUE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GLUE. When comparing the yearly performance of all stocks, GLUE is one of the better performing stocks in the market, outperforming 97.3% of all stocks.
GLUE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GLUE. While GLUE has a great health rating, its profitability is only average at the moment.
GLUE Financial Highlights
Over the last trailing twelve months GLUE reported a non-GAAP Earnings per Share(EPS) of 0.31. The EPS increased by 116.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.54% | ||
| ROA | 4.56% | ||
| ROE | 8.52% | ||
| Debt/Equity | 0 |
GLUE Forecast & Estimates
15 analysts have analysed GLUE and the average price target is 29.87 USD. This implies a price increase of 63.41% is expected in the next year compared to the current price of 18.28.
For the next year, analysts expect an EPS growth of 72.12% and a revenue growth 431.8% for GLUE
GLUE Ownership
GLUE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.75 | 411.552B | ||
| AMGN | AMGEN INC | 16.85 | 201.047B | ||
| GILD | GILEAD SCIENCES INC | 17.12 | 192.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.07 | 121.106B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.05 | 83.892B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.66 | 43.941B | ||
| INSM | INSMED INC | N/A | 32.101B | ||
| NTRA | NATERA INC | N/A | 29.393B | ||
| BIIB | BIOGEN INC | 12.76 | 28.709B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.15 | 20.773B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GLUE
Company Profile
Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 147 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Company Info
MONTE ROSA THERAPEUTICS INC
321 Harrison Avenue, Suite 900
Boston MASSACHUSETTS US
CEO: Markus Warmuth
Employees: 147
Phone: 16179492643
MONTE ROSA THERAPEUTICS INC / GLUE FAQ
Can you describe the business of MONTE ROSA THERAPEUTICS INC?
Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 147 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
What is the stock price of MONTE ROSA THERAPEUTICS INC today?
The current stock price of GLUE is 18.28 USD. The price decreased by -0.44% in the last trading session.
Does GLUE stock pay dividends?
GLUE does not pay a dividend.
What is the ChartMill technical and fundamental rating of GLUE stock?
GLUE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the PE ratio for GLUE stock?
The PE ratio for MONTE ROSA THERAPEUTICS INC (GLUE) is 58.97. This is based on the reported non-GAAP earnings per share of 0.31 and the current share price of 18.28 USD.
How many employees does MONTE ROSA THERAPEUTICS INC have?
MONTE ROSA THERAPEUTICS INC (GLUE) currently has 147 employees.
What is the market capitalization of GLUE stock?
MONTE ROSA THERAPEUTICS INC (GLUE) has a market capitalization of 1.33B USD. This makes GLUE a Small Cap stock.